GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avantor Inc (NYSE:AVTR) » Definitions » Return-on-Tangible-Equity

AVTR (Avantor) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Avantor Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Avantor's annualized net income for the quarter that ended in Mar. 2025 was $258 Mil. Avantor's average shareholder tangible equity for the quarter that ended in Mar. 2025 was $-2,892 Mil. Therefore, Avantor's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was Negative Tangible Equity%.

The historical rank and industry rank for Avantor's Return-on-Tangible-Equity or its related term are showing as below:

AVTR' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: Negative Tangible Equity

AVTR's Return-on-Tangible-Equity is ranked better than
99.87% of 756 companies
in the Medical Devices & Instruments industry
Industry Median: 2.585 vs AVTR: Negative Tangible Equity

Avantor Return-on-Tangible-Equity Historical Data

The historical data trend for Avantor's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avantor Return-on-Tangible-Equity Chart

Avantor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Avantor Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Competitive Comparison of Avantor's Return-on-Tangible-Equity

For the Medical Instruments & Supplies subindustry, Avantor's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avantor's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avantor's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Avantor's Return-on-Tangible-Equity falls into.


;
;

Avantor Return-on-Tangible-Equity Calculation

Avantor's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=711.5/( (-4239.4+-2942.4 )/ 2 )
=711.5/-3590.9
=Negative Tangible Equity %

Avantor's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=258/( (-2942.4+-2842)/ 2 )
=258/-2892.2
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Avantor  (NYSE:AVTR) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Avantor Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Avantor's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Avantor Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Executives
Gregory L Summe director C/O GLEN CAPITAL PARTNERS LLC, 800 SOUTH STREET, SUITE 160, WALTHAM MA 02453
Joseph R Massaro director 5725 DELPHI DRIVE, TROY MI 48098
Jonathan M Peacock director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lan Kang director 100 MATSONFORD ROAD, RADNOR PA 19087
James Bramwell officer: EVP, Strategic Partners C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Steven W Eck officer: SVP & Chief Accounting Officer C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462
Christophe Couturier officer: See Remarks 9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451
Benoit Gourdier officer: EVP, Biopharma Production 100 MATSONFORD ROAD, RADNOR PA 19087
Frederic Vanderhaegen officer: EVP, Europe C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Brittany Hankamer officer: EVP, Chief HR Officer 100 MATSONFORD ROAD, RADNOR PA 19087
R. Brent Jones officer: EVP, Chief Financial Officer C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050
Claudius Sokenu officer: EVP, Chief Legal & Compliance C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422
Randy Lee Stone officer: EVP, Proprietary Products 974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805
Gerard Brophy officer: EVP, Biopharma Production C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Kitty Sahin officer: EVP, Strategy&Corp Development 100 MATSONFORD ROAD, RADNOR PA 19087